Roivant Sciences Ltd (ROIV) Stock Analysis
Verdict: WATCH (do not buy)
Phase 2 Mosliciguat data validates pipeline potential, but a $29.5B cap on <$50M revenue leaves minimal margin for clinical slip-ups.
Investment score: 54/100
Analysis as of
Is Roivant Sciences Ltd stock worth reviewing? AI model thesis
The AI model views Roivant Sciences as a HOLD at $40.82. Recent positive Phase 2 trial results for Mosliciguat validate its clinical pipeline, but a $29.5B market cap against TTM revenues of $8.26M leaves little room for operational or regulatory errors.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Roivant Sciences Ltd opportunities and risks
What speaks for ROIV
- Phase 2 PHocus success for Mosliciguat in PH-ILD opens a multi-billion dollar commercial market opportunity.
What speaks against ROIV
- Extreme valuation dislocation relative to current revenue leaves zero room for trial failures.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ROIV | n/a | 3915.1x | n/a | 81.2% | -3534.9% | -2.8% |
| KNSA | 71.3x | 6.9x | 50.4x | 54.5% | 9.6% | 3.2% |
| CMPS | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.3% |
| IMCR | n/a | 4.1x | 99.1x | 98.8% | -2.3% | -3.8% |
| GNS.L | 5.0x | 2.2x | 11.7x | 47.7% | 43.4% | 5.4% |
| SLNCF | n/a | 1001.1x | n/a | 51.0% | -9759.2% | -6.9% |
| Peer median | n/a | 4.1x | 11.7x | 51.0% | 0.0% | -3.8% |
Frequently asked questions about Roivant Sciences Ltd (ROIV)
Is ROIV stock a good investment?
The cached TradeMates AI model rates Roivant Sciences Ltd as WATCH (do not buy) with an investment score of 54/100. The AI model views Roivant Sciences as a HOLD at $40.82. Recent positive Phase 2 trial results for Mosliciguat validate its clinical pipeline, but a $29.5B market cap against TTM revenues of $8.26M leaves little room for operational or regulatory errors. This is algorithmic model output, not personal investment advice.
Is ROIV stock a buy?
The TradeMates model verdict for ROIV is WATCH (do not buy) with an investment score of 54/100. Treat this as a model signal to review, not a personal buy recommendation.